Chin J Infect Dis , J une 2002 ,Vol 20 ,No . 3
Reverse Transcriptase Inhibitors , NN R TIs) 3
1995-2005 Tsinghua Tongfang Optical Disc Co., Ltd. All rights reserved.
Chin J Infect Dis , J une 2002 ,Vol 20 ,No . 3
1995-2005 Tsinghua Tongfang Optical Disc Co., Ltd. All rights reserved.
Chin J Infect Dis , J une 2002 ,Vol 20 ,No . 3
de Wolf F , Lange J M , Goudsmit J , et al. Effect of zidovudine on
serum human immunodificiency virus antigen levels in symptom2
free subject s. Lancet , 1988 ,1 (8582) :3732376.
Concorde Coordinating committee. Concorde : MRC/ ANRS ran2
domized double2blind controlled trial of immediate and deferred zi2
dovudine in symptom2free HIV infection. Lancet , 1994 , 343
Fischl MA , Olson RM , Follansbee SE , et al. Zalcitabine com2
pared wit h zidovudine in patient s wit h advanced HIV21 infection
who received previous zidovudine t herapy. Ann Intern Med ,
Alpha International Coordinating committee. The alpha t rial : Eu2
ropean/ Aust ralian randomized double2blind trial of two doses of
didanosine in zidovudine2intolerant patients with symptomatic HV
Pauwels R , Andries K , Desmyter D , et al. Potent and selective
inhibitor of HIV21 replication in vitro by a novel series of TIBO
derivatives. Nat ure , 1990 ,343 (6257) :4702474.
Nunberg J H , Schleif WA , Boot s EJ , et al. viral resistance to hu2
man immunodeficiency virus type 12specific pyridinone reverse
t ranscriptase inhibitors. J Virol ,1991 ,65 :488724892.
Schooley R T , Ramirez2Ronda C , Lange J M , et al. Virologic and
immunologic benefit s of initial combination t herapy wit h zidovu2
dine and zalcitabine or didanosine compared wit h zidovudine
monot herapy. J Infect Dis ,1996 ,173 :135421366.
Markowitz M , Saag M , Powderly W G , et al. A preliminary
st udy of ritonavir , an inhibitor of HIV21 protease , to treat HV21
infection. N Engl J Med , 1995 ,333 :153421539.
Masci J R. : outpatient management of HIV infection , CRC Press
1995-2005 Tsinghua Tongfang Optical Disc Co., Ltd. All rights reserved.
Chin J Infect Dis , J une 2002 ,Vol 20 ,No . 3
Constantine N T. Quality assurance and standardization n clinical
ity Mortalit y Weekly Report ,47 ( RR27) 1998 ,1233.
diagnostic immunological and molecular assays for human immun2
Onway B. Adherence and Directly Observed Therapy ( DO T) .
odeficiency. virus , in Nakancia RM , Burek Cl , Cook L , et al
In : Internet Conference Report s , Dec. 16219 , 2001 , Chicago ,
( eds :) Clinical diagnostic immunology2Blackweel Science Inc.
US Dept . of Healt h and Human Services : Guideline for t he use of
Wei X , Ghosh S K , Taylor M E , et al. Viral dynamics in human
antiret roviral agent s in HIV2infected adults and adolescents.
immunodeficiency virus type 1 infection. Nat ure , 1995 ,373 :1172
Wahington DC : US Dept . of Healt h and Human Services ;
Lange J MA. and Montaner , J SG. : Anti2retroviral therapy and
Roche and Trimeris Release : 48 week result s of two phase II
resistance to anti2retroviral drug , In : Schuitemaker , H and
st udies of Inhibitor T220 , at 9th Retrovirus Conference in Seattle ;
Miedema , F. : AIDS pat hogenesis , Kluwer Academic Publish2
Rust schman O T , Opravil M , Iten A , et al. A placebo2controlled
Carpenter CCJ , Fischl MA , Hammer SM , et al. Antiret roviral
t rial of didanosine plus stavudine wit h and wit hout hydroxyurea
t herapy for HIV infection in 1998 : updated recommendations of
for HIV infection. AIDS , 1998 ,12 : F712F77.
t he International AIDS Society2USA Panel. J AMA , 1998 ,280 :
Standst rom E , Wahren B , and Nordic VAC204 study Group :
Therapeutic immunization wit h recombinant gp 160 in HIV21 in2
Karen M (ed) : HIV and AIDS2A global view , Greenwood Press ,
USA , 2002 , xii2xiii , 1832199 :2532271.
Notermans DW , J urriaans S , De Wolf , F , et al. Decrease of
Kang L Y , Pan XZ , Yang WX , et al. Molecular st udies on effica2
HIV21 RNA levels in lymphoid tissue and peripheral blood during
cy of Chinese herbal formula XQ29301 for AIDS treatment . XIII
t reat ment wit h ritonavir , lamivudine and zidovudine. AIDS ,
International AIDS Conference Abst ract s : Volumn II , 2000 ,
P355 abst ract ThPeB5 192. Durban ,SA ,9214 J ul ,2000.
Sepkowitz KA. Effect of HAAR T on Nat ural history of AIDS2re2
L undgreu J D , HAAR T interruption increase risk of AIDS and
lated opport unistic disorders. Lancet , 1998 ,351 :228.
deat h for most patient s , at t he 9th Conference on Ret roviruses and
Zhang H , Dornadulo G , Beumont M , et al. Human immunodefi2
Opport unistic infections in Seattle , WA , February 24228 ,2002.
ciency virus type 1 in t he semen of men receiving highly active an2
Bolye B. www. hivandhepatitis. com/ recent/ haart/ 022202b.
tiret roviral t herapy. New Engl J Med , 1998 ,339 :180321809.
Landay AL , Bettendore D , Chan E , et al. Evidence of Immune
Dirienzo A G , Vander Horst C , Finkelstein DM , et al. Efficacy
Reconstit ution in Antiret roviral Drug2Experienced with advanced
of Trimet hoprim2sulfamethoxazole for the prevention of bacterial
HIV Disease. J . AIDS Research and Human Ret roviruses , 2002 ,
infections in a randomized prophylaxis t rial of patient s wit h ad2
vanced HIV infection. AIDS Research and Human Ret roviruses ,
Shatter N , Chuachoowang R , Mock PA , et al. Short2course zi2
dovudine for perinatal HIV21 transmissions in Bangkok , Thai2
Xu J Q , Whit man L , Lori F , et al. Met hods of using Interleukin
land : a randomized cont rolled t rial. Lancet , 1999 ,333 :7732780.
2 to Enhance HIV2Specific Immune Response. AIDS Research
Centers for Disease Cont rol and Prevention : Public Healt h Service
and Human Ret roviruses ,2002 ,18 :2892293.
Guideline for t he management of healt h2care workers exposure to
HIV and recommendations for post2exposure prophylaxis Morbid2
1995-2005 Tsinghua Tongfang Optical Disc Co., Ltd. All rights reserved.
Pharma overtakes arms industry to top the league of misbehaviour GlaxoSmithKline's $3bn fine for mis-sel ing drugs in the US is the biggest ever handed down, but analysts say it is a drop in the ocean compared with the profits from medicines Terry Macalister The Observer, Sunday 8 July 2012 GSK's headquarters in Brentford, London. The firm has been handed a $3bn fine in the US for